Achieving Corporate Diversity and Inclusion Goals through investment and Policy Choices Grace Colón participated in an educational panel discussion regarding diversity and inclusion during BIO Investor Forum Digital 2020. A recent Nature Biotechnology article notes that less than 1% of the nearly 200 senior-level positions on investment teams...
Grace Colón presented Transforming Cardiovascular Treatment with Pulmonary Delivery at the Oppenheimer Private Life Sciences Company Call Series on 8/18/2020 with Host: Leland Gershell, Oppenheimer & Co. Inc. Grace presented how this is a major unmet market need Significant market (>30M patients globally; >$50B US healthcare...
Biotech2050 podcast which aired 6/18/2020 featuring our President and CEO Grace Colon! She shares how her passion for #engineering and #biotech lead to our breakthrough approach to treat #AFib. Hear our story here: https://bit.ly/37wTDN9 #WomenInSTEM #cardiovascular #clinicaltrials #medicaldevice #biotech #startup...
Our CEO Grace Colón moderated the "Digital Health in Respiratory Care – The Next Frontier" panel at Bio Digital Week 2020. More information below: While most of the attention in the use of digital health for chronic care management has gone to players in the diabetes,...
InCarda Therapeutics CEO Grace Colón, PhD, meets with CG Life Managing Partner Erik Clausen at Biotech Showcase 2020 to discuss unmet needs in cardiovascular health. She provides an update on the company’s development of first-of-their-kind inhaled therapies for cardiovascular diseases, including atrial fibrillation. Dr. Colón...
June 3-6, 2019 - Philadelphia, PA “Addressing Unmet Need in Cardiovascular Disease” Panel At the 2019 Biotech Industry Organization’s (BIO) International Conference held in June in Philadelphia, InCarda’s CEO, Dr. Grace Colon, was a participant on a panel of distinguished experts entitled “Addressing Unmet Need in Cardiovascular...
March 19, 2019 - San Diego, CA InCarda’s Mick Hurrey, Ph.D. presented the unique product development path taken for InRhythm, InCarda’s novel treatment in development for Paroxysmal Atrial Fibrillation. In his cleverly titled presentation “Every Breath You Take is a Shot Through the Heart,” Mick described...
May 7, 2019 - Palo Alto, CA At the 2019 Stanford Biodesign New Arrhythmia Technologies Retreat, InCarda’s Chief Medical Officer, Dr. Luiz Belardinelli, provided an overview of the pre-clinical and clinical development for InRhythm (flecainide for inhalation). Dr. Bellardinelli explained to the audience of cardiology experts...
May 6-7, 2019 - San Diego, CA “A drug delivery 2.0 conference addressing the emerging needs for best routes of delivery” - Carlos Schuler, InCarda COO, CTO and Co-founder presented at the recent Drug Delivery West conference. ...
Former Chairman and CEO of InterMune Brings Extensive Development and Commercialization Experience to Support Continued Advancement of InRhythm™ for Treatment of Atrial Fibrillation SAN FRANCISCO, CA – April 3, 2019 – InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases,...